Your diabetes care team can help determine whether medication adjustment is appropriate based on your HbA1c levels, weight loss progress, and quality of life considerations
Nausea, which affected 18-36% of participants at the 4 mg dose and 17-60% at the 8 mg dose in clinical trials, usually peaks during the first week of each new dose level and then subsides as the body adapts
Glucagon-like peptide 1 (GLP-1) is a peptide incretin hormone that is naturally released by the cells of the intestine when people consume food, reducing blood glucose levels
Supports a gut environment where GLP-1 thrives*: Eriomin and Feiolix promote a healthy metabolic environment by supporting gut health and maintaining balanced oxidative stress and inflammation responses.
Ibis B, et al
Each generation of weight loss peptide activates more receptors, starts at a dose calibrated for that receptor load, and achieves greater weight loss at the therapeutic range